Low molecular heparin in a pregnant woman with mechanical cardiac valve prosthesis;Lavmolekylaert heparin ved mekanisk hjerteventil og graviditet

Tidsskrift for den Norske Laegeforening

Volumn 119, Issue 29, 1999, Pages 4319-4320

  Abildgaard, U ^a   Gjestvang, F T ^b   Lossius, P ^c   Hodne, E ^d  

^a Medisinsk Klinikk   (Norway)

^b Medisinsk avdeling   (Norway)

^c Vest Agder Sentralsykehus   (Norway)

^d NONE   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULATION; ARTICLE; CASE REPORT; ECHOCARDIOGRAPHY; FEMALE; HEART VALVE PROSTHESIS; HUMAN; PREGNANCY; SUBCUTANEOUS DRUG ADMINISTRATION; TERATOGENICITY; THROMBOSIS;

ADULT; ANTICOAGULANTS; FEMALE; FIBRINOLYTIC AGENTS; HEART VALVE PROSTHESIS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LABOR, INDUCED; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY OUTCOME; THROMBOSIS;

EID: 0033619721     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Åstedt B. Antenatal drugs affecting vitamin K status of the fetus and the newborn. Semin Thromb Haemost 1995; 21: 364-70.
2. Dale J, Myhrc E, Storstein O, Stormorken H, Efskind L. Prevention of arterial thromboembolisra with acetylsalisylic acid. A controlled clinical study in patients with aortic ball valves. Am Heart J 1977; 94: 101-11.
3. Lécuru F, Desnos M, Taurelle R. Anticoagulant therapy in pregnancy. Report of 54 cases. Acta Obstet Gynecol Scand 1996; 75: 217-21.
4. Iturre-Alessio I, Fonseca MD, Mutchinick O, Santos MA, Zajarias A, Salazar E. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 1986; 315: 1390-3.
5. Salazar E, Izaguirre R, Verdejo J, Mutchinick O. Failure of adjusted dose of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses. J Am Coll Cardiol 1996; 27: 1698-703.
6. Study group of the European Society of Cardiology. Guidelines for prevention of thromboembolic events in valvular heart disease. Eur Heart J 1995; 16: 1320-30.
7. Tiede DJ, Nishimura RA, Gastineau DA, Mullany CJ, Orszulak TA, Schaff UV. Modern management of prosthetic valve anticoagulation. Mayo Clin Proc 1998; 73: 665-80.
8. Handeland G, Abildgaard U, Holm HA, Arnesen KE. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 1990; 39: 107-12.
9. Holm HA, Abildgaard U, Kalvenes S. Heparin assays and bleeding complications in treatment of deep venous thrombosis with particular reference to retroperitoneal bleeding. Thrombos Haemost 1985; 53: 278-81.
10. Ginsberg JS, Barren WM. Pregnancy and prosthetic heart valves. Lancet 1994; 344: 1170-2.
11. Elkayam U. Anticoagulation in pregnant women with prosthetic heart valves: a double jeopardy. J Am Coll Cardiol 1996; 27: 1704-6.
12. Harenberg J. Thromboembolieprophylaxe mit niedermolekularem Heparin in der Schwangerschaft. Geburtsh Frauenheilk 1987; 47: 15-8.
13. Lee LH, Liauw PCY, Ng ASH. Low molecular weight heparin for thromboprophylaxis during pregnancy in 2 patients with mechanical mitral valve replacements. Thrombos Haemost 1996; 76: 628-30.